Fulcrum Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 611c
August 26, 2019 7:13 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($9.21), $6.11 worse than the analyst estimate of ($3.10).
Second Quarter 2019 and Recent Business Highlights
In August 2019, Fulcrum announced that it initiated ReDUX4, its Phase 2b clinical trial evaluating losmapimod for the treatment of FSHD.In August 2019, Fulcrum announced that it initiated a Phase 2 open label clinical trial evaluating losmapimod for the treatment of FSHD.In July 2019, Fulcrum completed its initial public offering of common stock, raising $72.0 million in gross proceeds.Second Quarter 2019 Financial Results
Cash Position: As of June 30, 2019, cash and... More